Novo Nordisk is searching for offers greater than ever earlier than, the CEO of the Danish drugmaker mentioned in an interview with CNBC on Wednesday.
“If our ambition is to assist a whole lot of thousands and thousands of sufferers on the market, then we’d like not simply the most effective, however the broadest pipeline on the planet,” mentioned Novo Nordisk CEO Mike Doustdar. “So let’s go and see who else principally has property which might be complementary to what we now have. And we’re fairly lively with these [business development] talks and acquisitions, and you may see extra of these as properly going ahead.”
Novo created the marketplace for GLP-1 weight reduction medicine with its weekly photographs Ozempic and Wegovy. Extra lately, the corporate has confronted issues from analysts about whether or not Novo’s pipeline is powerful sufficient for it to stay a pacesetter within the more and more aggressive weight problems drug area.
Mike Doustdar, chief government officer of Novo Nordisk A/S, throughout an interview in New York, US, on Wednesday, Feb. 11, 2026.
Michael Nagle | Bloomberg | Getty Photos
Rival Eli Lilly has already overtaken Novo in market share for weekly GLP-1 photographs, although Novo has taken an early lead within the new class of GLP-1 drugs for weight reduction.
Doustdar mentioned he disagrees with the issues about Novo’s upcoming therapies, arguing the drugmaker has “top-of-the-line pipelines within the business.” He pointed to Novo’s CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes can be authorized on the finish of this 12 months, and an experimental amylin-targeting drug referred to as zenagamtide that Novo has accelerated growth of, amongst different property.
“In fact, there’s quite a lot of issues in my pipeline that proper now I’ve the aware of look into and get excited (about) however not have shared it but with the world,” he mentioned. “So I’m extremely enthusiastic about our pipeline, and I might simply say to the traders who’re just a little bit skeptical, wait and see.”
Doustdar spoke to CNBC after the corporate mentioned its Wegovy capsule carried out higher than anticipated within the first quarter, and it raised its full-year revenue steerage.
